Regeneron Pharmaceuticals announced it will present new clinical data and research on treatments for metabolic diseases, eye conditions, and rare diseases at the ADA and ENDO medical meetings in June 2026. Highlights include Phase 2 trial results on trevogrumab for muscle health in obesity and Phase 3 data on garetosmab for fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder. The presentations also cover early research on Graves' and thyroid eye disease. These updates showcase Regeneron's progress in addressing serious diseases with unmet medical needs, potentially impacting future treatment options.
CytomX Therapeutics has expanded its collaboration with Regeneron Pharmaceuticals to develop conditionally-activated bispecific cancer therapies using their PROBODY and Veloci-Bi platforms. CytomX will receive a $37 million payment for two new target...
Pomerantz LLP is investigating Regeneron Pharmaceuticals for potential securities fraud after the company announced that its Phase 3 trial for a melanoma drug combo failed to meet key goals. The news caused Regeneron's stock to drop nearly 10%. The i...
